Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA
NCT06955897 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 45
Last updated 2026-05-14
Summary
The purpose of this project is to investigate the utility of the SMA EFFORT, an SMA-specific patient-reported outcome measure, to assess perceived physical fatigability that is anchored to intensity and duration of activities. We aim to characterize perceived physical fatigability (PPF) in a diverse cohort of people with SMA (pwSMA) and evaluate the change of PPF before and after nusinersen dosing.
Conditions
Interventions
- OTHER
-
Observational
Observational
Sponsors & Collaborators
- collaborator INDUSTRY
- lead OTHER
Principal Investigators
-
Jacqueline Montes, Pt, EdD · Columbia University
Eligibility
- Min Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-04-24
- Primary Completion
- 2026-12-07
- Completion
- 2027-02-26
Countries
- United States
Study Locations
More Related Trials
-
Characterization of New Phenotypes of Patients With Spinal Muscular Atrophy Treated With SMN Restoring Therapy
NCT06321965 ·Status: RECRUITING ·Phase: NA
-
Oxidative Capacity and Exercise Tolerance in Ambulatory SMA
NCT02895789 ·Status: COMPLETED
-
Personalized Medicine for SMA: a Translational Project
NCT05779956 ·Status: UNKNOWN
-
An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)
NCT02052791 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
NCT04089566 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).
NCT02462759 ·Status: TERMINATED ·Phase: PHASE2
-
Pulmonary Function Test Changes and Respiratory Muscle Strength Trends in Spinal Muscular Atrophy Patients Receiving Nusinersen Treatments
NCT04050852 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Spinraza in Adult Spinal Muscular Atrophy
NCT03709784 ·Status: ACTIVE_NOT_RECRUITING
-
Study of the Functional Effects of Nusinersen in 5q-spinal Muscular Amyotrophy Adults (SMA Type 2 or 3 Forms)
NCT04576494 ·Status: COMPLETED ·Phase: NA
-
A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies
NCT02594124 ·Status: COMPLETED ·Phase: PHASE3
-
Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)
NCT02865109 ·Status: NO_LONGER_AVAILABLE
-
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
NCT05337553 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Diagnostic Journey, Patient Experience, and Disparities in the Treatment of Spinal Muscular Atrophy (SMA) in the MedStar Health System
NCT07223489 ·Status: RECRUITING
-
An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)
NCT01494701 ·Status: COMPLETED ·Phase: PHASE1
-
Responsiveness and Validation Study of MFM-32 in SMA Patients Treated With Nusinersen
NCT04602195 ·Status: COMPLETED
-
Clinical Study of Spinal Muscular Atrophy
NCT00443066 ·Status: COMPLETED
-
A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)
NCT04729907 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Antisense Oligonucleotide for Spinal Muscular Atrophy
NCT05187260 ·Status: UNKNOWN
-
Ultrasound-assisted vs Landmark Based Intrathecal Administration of Nusinersen
NCT04674618 ·Status: COMPLETED ·Phase: NA
-
A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy
NCT02193074 ·Status: TERMINATED ·Phase: PHASE3
-
The Effect of Aerobic Exercise Training in Patients With Type III Spinal Muscular Atrophy
NCT05544994 ·Status: UNKNOWN ·Phase: NA
-
Measuring Levels of SMN in Blood Samples of SMA Patients
NCT00061607 ·Status: COMPLETED
-
Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies
NCT06532474 ·Status: RECRUITING
-
Characterization of the Clinical-epidemiological Profile of Patients With SMA5q Types II and III: Observational Study
NCT04404764 ·Status: COMPLETED
-
Clinical Trial of Exercise in Patients With Spinal Muscular Atrophy (SMA)
NCT01166022 ·Status: COMPLETED ·Phase: NA